Evaluation of cardiac markers in patients with breast cancer receiving antineoplastic treatment: a systematic review.

Abstract

<h4>Background</h4>Cardiac markers are important in the diagnosis of heart and coronary insufficiency, it is through them that they can measure the damage to cardiac fibers resulting from these diseases. Recent research has shown that the levels of biomarkers are altered who have neoplasms under chemotherapy treatment without these patients having any clinical manifestations. The research was to conduct a systematic review of the main cardiac biomolecular markers in scientific publications bases and to verify how their levels present in individuals with breast cancer, as well as to analyze the influence of antineoplastic treatment in the circular levels of these markers resulting from the effects of cardiac damage on patient therapy and which are good predictors of cardiovascular diseases related to chemotherapy treatment.<h4>Methods</h4>Medline, Lilacs and Cochrane and in these databases, systematic searches of publications were carried out between the years 2010 and 2020 using the descriptors "Mesh" or the equivalent in the chosen database. Studies that evaluated the following cardiac biomarkers: troponin, pro-type B natriuretic peptide (proBNP)/N-terminal pro-BNP (NT-proBNP), myoglobin, creatine kinase-MB fraction, fibrinogen, and D-dimer.<h4>Results</h4>At the end, 31 published articles were obtained for analysis in which cardiac markers ultra-sensitive troponin I and T, myoglobin, and NT-proBNP showed to be the best predictors of cardiotoxicity for breast cancer patient under chemotherapy.<h4>Conclusions</h4>The ultra-sensitive cardiac markers troponin I and T, NT-proBNP and myoglobin, were the ones that provided the best biomarkers in detecting cardiotoxicity, requiring continuous research and research for cardiotoxic biomarkers.